A NEW DAWN
in disease early interception
Featured
MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.
Learn More
MiRXES closes US$77 million Series C funding to accelerate multi-cancer early detection tests and preventive healthcare globally. This round was led by CR-CP Life Science Fund, and joined by Rock Springs Capital, EDBI, and established global financial institutions.
This new investment will be used primarily to fund the development and commercialization of MiRXES’ pipeline of multi-cancer early detection tests that look for blood borne microRNA and other molecular signatures released by cancer and immune cells. The funds will also be used to accelerate regulatory approval and adoption of GASTROClear in China, Japan, selected countries in Asia, Europe and Americas that have high rates of gastric cancer.
Whenever we fall sick, we often associate each illness with a characteristic set of symptoms. Constantly sneezing with a bad rash? Must be allergies. Stuffy nose and sore throat? Likely the flu. Bloodshot eyes? Likely conjunctivitis or pink eye. But not all diseases come with obvious symptoms.
Our Science & Pipeline
At MiRXES, we harness the power of RNA to deliver early, actionable and personalized diagnoses across the care continuum to improve and save lives. Prevention is better than cure.
With early detection, mitigating risk factors and implementing prevention strategies, most cancer deaths can be prevented.
Our science opens us to a world without late-stage cancer diagnoses. This is how we improve and save lives.
MiRXES endeavors to be at the forefront of disease early detection and interception.
Delivering Our Solutions
One in four people has cancer in the world today. At MiRXES, we know the importance of science in the fight against cancer.
We understand that to make the most impact in improving and saving lives, we must translate and deliver our innovative solutions from the lab to clinic.
Read more about how our solutions that range from industry-leading discovery tools and services to diagnostic tests for cancer, cardiovascular, metabolic and infectious diseases, and precision oncology can enable you to act sooner – when it matters most.
SOCIAL MEDIA
